-
Exclusive: Idera CEO Discusses The Potential For His Company's Lead Drug Candidate
Thursday, April 20, 2017 - 2:15pm | 1282Idera Pharmaceuticals Inc (NASDAQ: IDRA) is a clinical stage biotech that has recently re-focused its pipeline to focus on oncology, starting with melanoma. The company has seen its share price rise 50 percent in 2017. In March, JMP Securities initiated coverage of the company at Market Outperform...